Vaxxinity, Inc. VAXX
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $15.5M
- P/E
- 0.0×
Follow VAXX
| Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | — | — |
P/S ratio |
— | — | 2,347.83 | 1,822.86 | — | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | — | — |
P/Operating CF |
— | — | (30.77) | (53.97) | — | — |
P/B ratio |
— | — | 3.34 | 0.00 | — | — |
Price to Tangible BV |
— | — | 3.72 | 0.00 | — | — |
EV/Sales |
— | — | 1,611.58 | 1,696.24 | — | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | — | (3.64) | (13.52) | — | — |
EV/FCF |
— | — | (3.56) | (13.26) | — | — |
Quick Ratio |
1.73 | 2.86 | 5.29 | 0.79 | 0.04 | — |
Current Ratio |
1.89 | 3.03 | 5.61 | 0.91 | 0.07 | — |
Net Debt/EBITDA |
0.30 | 0.99 | 1.09 | 0.65 | (0.05) | — |
Debt/Assets |
29.93% | 12.26% | 6.19% | 21.34% | 70.47% | 0.00% |
Debt/Equity |
0.99 | 0.21 | 0.08 | (0.12) | (0.02) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.02 | 0.00 | — |
Operating CF/Net income |
1.01 | 0.74 | 0.59 | 0.85 | 0.86 | — |
Capex/Depreciation |
(1.10) | (2.61) | (0.97) | (1.79) | 0.00 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (150.65%) | (78.85%) | (665.19%) | 58.81% | 20.93% | — | |
| (75.55%) | (55.09%) | (126.54%) | (154.46%) | (1,782.95%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(213.19%) | (99.69%) | (98.56%) | (471.52%) | 77.78% | — |
Average Days of Receivables |
— | 0.00 | 2,173.41 | 17.04 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 108,150.00% | 3,693.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 78,522.73% | 2,193.36% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 46,078.79% | 182.05% | 0.00% | — |
Graham Net Nets |
— | — | 0.27 | (0.17) | — | — |
Graham Number |
— | — | 0.00 | 0.00 | — | — |
Earnings Yield |
— | — | (31.71%) | (9.31%) | — | — |
Free Cash Flow Yield |
— | — | (19.28%) | (7.02%) | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | — |
Operating CF per Share |
(0.45) | (0.44) | (1.06) | (0.52) | (0.36) | — |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.02) | 0.00 | — |
Free Cash Flow per Share |
(0.46) | (0.46) | (1.07) | (0.54) | (0.36) | — |
Cash per Share |
0.24 | 0.70 | 1.89 | 0.47 | 0.01 | — |
Shareholders Equity per Share |
0.11 | 0.49 | 1.68 | (1.33) | (1.42) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.11 | 0.49 | 1.68 | (1.33) | (1.42) | — |
Free Cash Flow |
(58.04) | (57.79) | (82.31) | (35.39) | (12.26) | — |
Working Capital |
15.63 | 62.95 | 126.81 | (3.68) | (18.44) | — |
Capital Expenditures |
(0.80) | (1.87) | (1.32) | (1.48) | — | — |
Net Current Asset Value |
2.33 | 49.67 | 116.25 | (101.84) | (48.67) | — |
EV/EBIT |
— | — | 0.00 | 0.00 | — | — |
Capex to Sales |
0.00 | 0.00 | 19.97 | 2.65 | — | — |
Net Profit Margin |
0.00% | 0.00% | (207,840.91%) | (7,173.61%) | 0.00% | — |
Price to Operating Income |
— | — | 0.00 | 0.00 | — | — |
| Other line items | ||||||
Depreciation/Fixed assets |
0.07 | 0.06 | 0.11 | 0.07 | 0.67 | — |
Cash ROIC |
(119.50%) | (41.95%) | (32.87%) | 101.17% | 26.49% | — |
Accounts Receivable Turnover |
— | 0.00 | 0.32 | 3.39 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.40 | 0.92 | 0.05 | 0.01 | — |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 1,147.67 | 601.49 | 7,138.56 | 4,380.00 | — |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
— | 0.55 | 0.21 | 0.16 | 0.35 | — |
Average Payables |
3.54 | 4.24 | 2.10 | 1.15 | 7.69 | — |
Average Assets |
75.36 | 136.54 | 108.41 | 25.87 | 0.80 | — |
Average Common Equity |
37.79 | 95.40 | 20.62 | (67.94) | (67.94) | — |
Columns are period end dates